SP
Stuart Poulton
EVP, Chief Development Officer

Stuart Poulton insider trades: Karyopharm Therapeutics (KPTI) stock sales

EVP, Chief Development Officer, Karyopharm Therapeutics Last trade Jul 28, 2026 18 Form 4 filings
$8K
Sold, last 12 months
3 sales
$0
Bought, last 12 months
0 buys
12
Open-market trades
since 2023
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Stuart reports to the SEC

Open-market buys and sales

12 trades reported on SEC Form 4, newest first

DateStockTypeValue
Jul 28, 2026KPTI↓ Sell$1K
May 14, 2026KPTI↓ Sell$4K
Feb 17, 2026KPTI↓ Sell$3K
Sep 15, 2025KPTI↓ Sell$3K
Jul 29, 2025KPTI↓ Sell$835
Mar 4, 2025KPTI↓ Sell$22K
Feb 18, 2025KPTI↓ Sell$4K
Jul 30, 2024KPTI↓ Sell$3K
Mar 1, 2024KPTI↓ Sell$26K
Feb 15, 2024KPTI↓ Sell$8K
Jul 28, 2023KPTI↓ Sell$5K
Feb 15, 2023KPTI↓ Sell$19K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other KPTI insiders

Open-market trades in the last 12 months

About Stuart Poulton's insider trades

Stuart Poulton is EVP, Chief Development Officer at Karyopharm Therapeutics (KPTI). Since Feb 15, 2023, Stuart has reported no open-market purchases and 12 sales worth $99K on SEC Form 4. In the last 12 months: 3 sales ($8K).

Their filings also include grants and awards (8 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KPTI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.